SEC EDGAR 6-KAug 5$INMD

InMode Ltd. (INMD): Financial results for Q2 2026

InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno

Original reporting

SEC EDGAR 6-K

Published Aug 5, 2026, 11:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 28, 2026, 7:25 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$INMD

Bearish

high confidence

Mentioned

$INMD

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR 6-K

Decision brief

The 30-second read

$INMDBearishMed

Why it matters

The earnings release shows flat revenue, margin compression, and modest guidance, likely prompting a sell‑off.

Market read

Primary earnings disclosure for a small‑cap biotech/med‑tech stock; relevant for traders tracking earnings momentum.

What to watch

Record consumables revenue in Asia and ongoing share repurchase may provide longer‑term support.

Relevance 7/10Novelty 8/10Timing: post‑market release on Aug 5 2026

Background

InMode Ltd., a Nasdaq‑listed medical‑technology company, filed a Form 6‑K reporting its Q2 2026 results and FY guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INMDBearishHigh confidence

Context

Q2 2026 GAAP revenue of $95.6M and FY 2026 guidance of $365‑$375M were disclosed for the first time.

Expected impact

Potential short‑term downside as investors digest weaker margins and modest guidance.

Evidence & confidence

Revenue unchanged YoY and operating margin fell from 24% to 13% (GAAP) signal slower growth; guidance remains below prior expectations.

Market effects

Sector

Medical‑device sector may see broader scrutiny of margin pressures.

Regional

Limited to U.S. and Israeli markets where InMode operates.

Global

Minimal global impact; primarily affects InMode shareholders.

Counterpoint

What could challenge this read

Despite margin decline, cash position of $501M could fund strategic acquisitions and support upside.

Key entities

Company
InMode Ltd.
Nasdaq‑listed medical‑technology firm.
Executive
Moshik Itzkovich
Chief Financial Officer who commented on results.

Read at source ← All news

$INMDMed

Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer

Steel Partners Holdings L.P. set an October 30, 2026 expiration for its $16.75 per share all-cash offer for InMode Ltd. The company accuses InMode's board of breaching fiduciary duties and demands engagement. InMode has not provided diligence materials or engaged in good faith, according to Steel.

stocktitan.netOct 19

$INMDMedAI 8/10

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.

prnewswire.comAug 5

$INMDMed

InMode Confirms Receipt of Unsolicited Proposal

InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.

prnewswire.comJul 10

$INMDMedAI 9/10

InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD)

InMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.

yahoo.comJul 9

$INMDHighAI 9/10

InMode stock surges on Steel Partners’ $16.75 buyout offer By Investing.com

InMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.

investing.comJul 9

$CRBPMed

Corbus Q3 Loss Widens On Higher R&D Costs; CRB-701 Data Due In Q1 2027

Corbus Pharmaceuticals (CRBP) reported a wider Q3 2026 net loss of $37.75M, up from $23.34M a year earlier, due to higher R&D costs. The company's cash position is $88.34M, expected to fund operations through 2028. CRBP's CRB-701 trial is ongoing, with data expected in Q1 2027, and CRB-913 showed promising weight loss results in a Phase 1b trial.

rttnews.comNov 11